Sygnis Group is a highly qualified team specializing in technology consulting, research and development projects, 3D printing, biotechnology, nanotechnology and the implementation of short production series. We associate engineers, scientists, designers and experts. We help companies enter the era of Industry 4.0.
AREAS OF OPERATIONS
WORKSHOPS 3D DESIGN
SPECIALIZED MACHINES
CONSTRUCTION
RAPID
BUDGET / INDUSTRIAL
PROTOTYPING
3D PRINTERS
HARDWARE
3D BIOPRINTING
INNOVATIONS
SPM MICROSCOPY
SCIENTIFIC TEAM
MICROSCOPY
ULTRA-HIGH VACUUM UHV
3D TISSUE MODELS
NANOFABRICATION
OMICS NANOPARTICLES
WHERE ARE WE?
•
120+ people
•
3D bioprinting lab
• Over 2000 m2 of space
•
Microscopy lab
•
Production Hub
• ISO 7 cleanroom (ISO 13485)
Prototype and manufacturing lab
R&D PROJECTS/SCIENCE
CONSTRUCTING A MULTIFUNCTIONAL HYBRID 3D PRINTER WITH REAL-TIME QUALITY CONTROL SYSTEM
CREATING A BIOMATERIAL PRINTING TECHNOLOGY AND CONSTRUCTING A 3D BIOPRINTER FOR AUTOMATED CREATION OF BIONIC ORGANS POIR.01.01.01-00-0166/20(NCBR) budget: 9 895 190,81 PLN
ADVANCED BIOCOMPOSITES BIOG-NET
POIR.04.04.00-00-1792/18-00 (FNP)
Scientific and Economic Committee
budget: 20 898 921,93 PLN
SYGLASS LOW TEMPERATURE GLASS 3D PRINTING (SYGLASS) POIR.01.01.01-00-1326/17(NCBR)
cooperation with professor Ryszard Buczyński
budget: 2 763 410,00 PLN
UNIVERSAL MEDIA FOR CERAMIC, NON-CONDUCTIVE PASTES POIR.02.03.02-14-0128/18(PARP)
cooperation with dr hab. Jakub Kupecki
budget: 490 118,10 PLN
CEPT 2 - operator of the Rapid Prototyping Techniques Laboratory
membership in Silesian Nano Cluster, Cluster for Photonics and Fiber Optics,
Tech to the Rescue and Cambridge Innovation Center
Attachments
Original Link
Original Document
Permalink
Disclaimer
Sygnis SA published this content on 03 January 2023 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 11 January 2023 11:02:10 UTC.
Sygnis SA is a Poland-based company, which egages in Research and Development (R&D) activities. The Company is active in four segments: Bioconvergence, Nanotechnology, Power Engineering, and New Incremental Technologies. Bioconvergence is a segment in which research is conducted to prevent the shortage of organs for transplants by bioprinting organs and creating bionic models for drug testing. The Nanotechnology segment is focused on using solutions from the field of photoelectron spectroscopy, and critical atomic force microscopy in casual products. The Power Engineering segment is focused on new methods of energy storage for renewable energy and other sources. New Incremental Technologies is focused on the development of solutions regarding 3D printing. The Company cooperates with over 85 specialists such as physicists, mechatronics, chemists, engineers, designers, and sociologists, and is involved in multiple projects.
SYGNIS SA 
